Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Zaccheaus A Jeremiah, Yetunde Obazee, Godwin R Okogun, Teddy C Adias, Osaro Mgbere & Ekere J Essien. (2012) Impact of short-term antiretroviral therapy (START) on some fibrinolytic markers in HIV-infected Nigerian adults: preliminary findings from the START study. HIV/AIDS - Research and Palliative Care 4, pages 87-94.
Read now
Read now
Massimo Franchini, Dino Veneri, Gian Luca Salvagno, Franco Manzato & Giuseppe Lippi. (2006) Inherited Thrombophilia. Critical Reviews in Clinical Laboratory Sciences 43:3, pages 249-290.
Read now
Read now
Björn Wiman. (1999) Predictive value of fibrinolytic factors in coronary heart disease. Scandinavian Journal of Clinical and Laboratory Investigation 59:sup230, pages 23-31.
Read now
Read now
Articles from other publishers (43)
I. I. Patalakh, O. V. Revka, O. B. Kuchmenko, O. O. Matova, T. F. Drobotko & T. V. Grinenko. (2018) Clot formation and lysis in platelet rich plasma of healthy donors and patients with resistant hypertension. The Ukrainian Biochemical Journal 90:2, pages 67-75.
Crossref
Crossref
Paul Vulliamy, Scarlett Gillespie, Lewis S. Gall, Laura Green, Karim Brohi & Ross A. Davenport. (2017) Platelet transfusions reduce fibrinolysis but do not restore platelet function during trauma hemorrhage. Journal of Trauma and Acute Care Surgery 83:3, pages 388-397.
Crossref
Crossref
Mariya Negreva, Svetoslav Georgiev & Katerina Vitlianova. (2016) Early effects of paroxysmal atrial fibrillation on plasma markers of fibrinolysis. Medicine 95:45, pages e5184.
Crossref
Crossref
Seung H. Yoo, Emilee Venn, Lauren A. Sullivan & Christine S. Olver. (2016) Thromboelastographic evidence of inhibition of fibrinolysis after ε‐aminocaproic acid administration in a dog with suspected acute traumatic coagulopathy. Journal of Veterinary Emergency and Critical Care 26:5, pages 737-742.
Crossref
Crossref
Takuya Shimizu, Manabu Uematsu, Toru Yoshizaki, Jun-ei Obata, Takamitsu Nakamura, Daisuke Fujioka, Kazuhiro Watanabe, Yosuke Watanabe & Kiyotaka Kugiyama. (2016) Myocardial Production of Plasminogen Activator Inhibitor-1 is Associated with Coronary Endothelial and Ventricular Dysfunction after Acute Myocardial Infarction. Journal of Atherosclerosis and Thrombosis 23:5, pages 557-566.
Crossref
Crossref
Anjan K. Bongoni, David Kiermeir, Jonas Schnider, Hansjörg Jenni, Pavan Garimella, Andrea Bähr, Nikolai Klymiuk, Eckhard Wolf, David Ayares, Esther Voegelin, Mihai A. Constantinescu, Jörg D Seebach & Robert Rieben. (2015) Transgenic Expression of Human CD46 on Porcine Endothelium. Transplantation 99:10, pages 2061-2069.
Crossref
Crossref
Anne Sofie Gram, Else-Marie Bladbjerg, Jane Skov, Thorkil Ploug, Anders Sjödin, Mads Rosenkilde, Daniel Elenius Madsen & Bente Merete Stallknecht. (2015) Three months of strictly controlled daily endurance exercise reduces thrombin generation and fibrinolytic risk markers in younger moderately overweight men. European Journal of Applied Physiology 115:6, pages 1331-1338.
Crossref
Crossref
Tarek A. Abd El-Aziz & Noha A. Rezk. (2014) Relation of PAI-1 and TPA Genes Polymorphisms to Acute Myocardial Infarction and its Outcomes in Egyptian Patients. Cell Biochemistry and Biophysics 71:1, pages 227-234.
Crossref
Crossref
Shu He, Hans Johnsson, Michal Zabczyk, Kjell Hultenby, Håkan Wallen & Margareta Blombäck. (2017) Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates. Thrombosis and Haemostasis 111:03, pages 417-428.
Crossref
Crossref
Eulalia Valle-Garay, Angel H. Montes, Jose R. Corte, Alvaro Meana, Joshua Fierer & Victor Asensi. (2013) tPA Alu (I/D) Polymorphism Associates With Bacterial Osteomyelitis. The Journal of Infectious Diseases 208:2, pages 218-223.
Crossref
Crossref
Peter Willeit, Alexander Thompson, Thor Aspelund, Ann Rumley, Gudny Eiriksdottir, Gordon Lowe, Vilmundur Gudnason & Emanuele Di Angelantonio. (2013) Hemostatic Factors and Risk of Coronary Heart Disease in General Populations: New Prospective Study and Updated Meta-Analyses. PLoS ONE 8:2, pages e55175.
Crossref
Crossref
Burton E. SobelRegina M. HardisonSaul GenuthMaria M. BrooksRobert D. McBaneIIIIIIDavid J. SchneiderRichard E. PratleyKurt HuberRobert WolkAshok KrishnaswamiRobert L. Frye. (2011) Profibrinolytic, Antithrombotic, and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 124:6, pages 695-703.
Crossref
Crossref
David Karasek, Helena Vaverkova, Milan Halenka, Dagmar Jackuliakova, Zdenek Frysak, Ludek Slavik & Dalibor Novotny. (2010) Prothrombotic markers in asymptomatic dyslipidemic subjects. Journal of Thrombosis and Thrombolysis 31:1, pages 27-36.
Crossref
Crossref
SH Alzahrani & RA Ajjan. (2010) Review article: Coagulation and fibrinolysis in diabetes. Diabetes and Vascular Disease Research 7:4, pages 260-273.
Crossref
Crossref
Diana A. Gorog. (2010) Prognostic Value of Plasma Fibrinolysis Activation Markers in Cardiovascular Disease. Journal of the American College of Cardiology 55:24, pages 2701-2709.
Crossref
Crossref
M. BONZINI, A. TRIPODI, A. ARTONI, L. TARANTINI, B. MARINELLI, P.A. BERTAZZI, P. APOSTOLI & A. BACCARELLI. (2010) Effects of inhalable particulate matter on blood coagulation. Journal of Thrombosis and Haemostasis 8:4, pages 662-668.
Crossref
Crossref
Anna M Thøgersen, Torbjörn K Nilsson, Lars Weinehall, Kurt Boman, Mats Eliasson, Göran Hallmans & Jan-Håkan Jansson. (2009) Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years. Blood Coagulation & Fibrinolysis 20:5, pages 340-346.
Crossref
Crossref
R.A. Ajjan & R.A.S. Ariëns. (2009) Cardiovascular disease and heritability of the prothrombotic state. Blood Reviews 23:2, pages 67-78.
Crossref
Crossref
David Karásek, Helena Vaverková, Milan Halenka, Luděk Slavík & Dalibor Novotný. (2009) Endothelial haemostatic markers in members of families with familial combined hyperlipidemia. Thrombosis Research 123:3, pages 466-475.
Crossref
Crossref
Florian Stehling, Ralph Weber, Arzu Özcelik, Martina Bröcker, Lothar Volbracht, Hans-Christoph Diener & Elmar Busch. (2008) Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic therapy. Neuroscience Letters 441:1, pages 39-43.
Crossref
Crossref
Cheol Whan Lee, Jung-Min Ahn, Duk-Woo Park, Young-Hak Kim, Myeong-Ki Hong, Jae-Kwan Song, Jae-Joong Kim, Seong-Wook Park, Hyun-Sook Chi & Seung-Jung Park. (2008) Tissue plasminogen activator on admission is an important predictor of 30-day mortality in patients with acute myocardial infarction undergoing primary angioplasty. Atherosclerosis 196:1, pages 327-332.
Crossref
Crossref
Erhard Haus. (2007) Chronobiology of hemostasis and inferences for the chronotherapy of coagulation disorders and thrombosis prevention. Advanced Drug Delivery Reviews 59:9-10, pages 966-984.
Crossref
Crossref
Suzanne Q. van Veen, Joost C.M. Meijers, Marcel Levi, Thomas M. van Gulik & Marja A. Boermeester. (2007) EFFECTS OF INTRA-ABDOMINAL ADMINISTRATION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR ON COAGULATION, FIBRINOLYSIS AND INFLAMMATORY RESPONSES IN EXPERIMENTAL POLYMICROBIAL PERITONITIS. Shock 27:5, pages 534-541.
Crossref
Crossref
Ramzi A. Ajjan & Peter J. Grant. 2007. Cardiovascular Medicine. Cardiovascular Medicine
2803
2818
.
Ramzi Ajjan & Peter J. Grant. (2006) Coagulation and atherothrombotic disease. Atherosclerosis 186:2, pages 240-259.
Crossref
Crossref
Oskari J. Virtanen, Vappu Sirén, Juha Multanen, Markus Färkkilä, Ilmo Leivo, Antti Vaheri & Marjaleena Koskiniemi. (2006) Plasminogen activators and their inhibitors in human saliva and salivary gland tissue. European Journal of Oral Sciences 114:1, pages 22-26.
Crossref
Crossref
James J. OliverDavid J. WebbDavid E. Newby. (2005) Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology 25:12, pages 2470-2479.
Crossref
Crossref
Sean I. SavitzGottfried SchlaugLouis CaplanMagdy Selim. (2005) Arterial Occlusive Lesions Recanalize More Frequently in Women Than in Men After Intravenous Tissue Plasminogen Activator Administration for Acute Stroke. Stroke 36:7, pages 1447-1451.
Crossref
Crossref
P.M. MANNUCCI, L. BERNARDINELLI, L. FOCO, M. GALLI, F. RIBICHINI, M. TUBARO & F. PEYVANDI. (2005) Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. Journal of Thrombosis and Haemostasis 3:2, pages 280-286.
Crossref
Crossref
Arvid Nordenhem, Karin Leander, Johan Hallqvist, Ulf de Faire, Margareta Sten-Linder & Björn Wiman. (2005) The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project. Thrombosis Research 116:3, pages 223-232.
Crossref
Crossref
T. Hrafnkelsdottir, T. Gudnason, U. Wall, C. Jern & S. Jern. (2004) Regulation of local availability of active tissue‐type plasminogen activator in vivo in man. Journal of Thrombosis and Haemostasis 2:11, pages 1960-1968.
Crossref
Crossref
Aruna D. PradhanAndrea Z. LaCroixRobert D. LangerMaurizio TrevisanCora E. LewisJudith A. HsiaAlbert ObermanJane M. KotchenPaul M Ridker. (2004) Tissue Plasminogen Activator Antigen and D-Dimer as Markers for Atherothrombotic Risk Among Healthy Postmenopausal Women. Circulation 110:3, pages 292-300.
Crossref
Crossref
Lars JohanssonJan-Håkan JanssonBirgitta StegmayrTorbjörn K. NilssonGöran HallmansKurt Boman. (2004) Hemostatic Factors as Risk Markers for Intracerebral Hemorrhage. Stroke 35:4, pages 826-830.
Crossref
Crossref
Melinda L. Ramsby. 2004.
111
133
.
Å. Johansson, K. Boman, K. Cederquist, H. Forsberg & T. Olsson. (2001) Increased levels of tPA antigen and tPA/PAI‐1 complex in myotonic dystrophy. Journal of Internal Medicine 249:6, pages 503-510.
Crossref
Crossref
Masami Hoshino, Yoshikura Haraguchi, Hiroyuki Hirasawa, Motohiro Sakai, Hiroshi Saegusa, Kazushiro Hayashi, Naoki Horita & Hiroyuki Ohsawa. (2001) Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas. Critical Care 5:2.
Crossref
Crossref
F. Bachmann. 2001. Fibrinolytics and Antifibrinolytics. Fibrinolytics and Antifibrinolytics
57
89
.
Björn WimanTomas AnderssonJohan HallqvistChristina ReuterwallAnders AhlbomUlf deFaire. (2000) Plasma Levels of Tissue Plasminogen Activator/Plasminogen Activator Inhibitor-1 Complex and von Willebrand Factor Are Significant Risk Markers for Recurrent Myocardial Infarction in the Stockholm Heart Epidemiology Program (SHEEP) Study. Arteriosclerosis, Thrombosis, and Vascular Biology 20:8, pages 2019-2023.
Crossref
Crossref
Henri BounameauxEgbert K. O. Kruithof. (2000) On the Association of Elevated tPA/PAI-1 Complex and von Willebrand Factor With Recurrent Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology 20:8, pages 1857-1859.
Crossref
Crossref
Björn Wiman. (2000) THE FIBRINOLYTIC ENZYME SYSTEM. Hematology/Oncology Clinics of North America 14:2, pages 325-338.
Crossref
Crossref
Lars JohanssonJan-Håkan JanssonKurt BomanTorbjörn K. NilssonBirgitta StegmayrGöran Hallmans. (2000) Tissue Plasminogen Activator, Plasminogen Activator Inhibitor-1, and Tissue Plasminogen Activator/Plasminogen Activator Inhibitor-1 Complex as Risk Factors for the Development of a First Stroke. Stroke 31:1, pages 26-32.
Crossref
Crossref
Wayne L Chandler, Marcy L Jascur & Paul J Henderson. (2000) Measurement of Different Forms of Tissue Plasminogen Activator in Plasma. Clinical Chemistry 46:1, pages 38-46.
Crossref
Crossref
G. Falk, G.-C. Sul, S. Schulman & B. Wiman. (1999) Detection of a new polymorphism in the PAI-1 gene located in the pro-peptide coding region. Fibrinolysis and Proteolysis 13:1, pages 26-30.
Crossref
Crossref